Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Kineta Inc.
Namida Lab
Imperial College London
Hamilton Health Sciences Corporation
Charite University, Berlin, Germany
SpeciCare
KU Leuven
Threshold Pharmaceuticals
National Cancer Institute (NCI)